Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regeneron PharmaceuticalsLTS:0R2M -0.57%89 EV-to-EBITDA is 13.47 as of Aug. 15, 2026, which is 11% below its 10-year median of 15.22. GuruFocus rates LTS:0R2M with a GF Score™ of 89/100 and a GF Value™ of $865.71 (Fairly Valued). The stock has 7 warning signs investors should review. Among 400 Biotechnology companies, Regeneron Pharmaceuticals ranks worse than 50.25% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Regeneron Pharmaceuticals's enterprise value is $77,434 Mil.
Regeneron Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $5,750 Mil. Therefore, Regeneron Pharmaceuticals's EV-to-EBITDA for today is 13.47.
The historical rank and industry rank for Regeneron Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
LTS:0R2M'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.36 Med: 15.22 Max: 37.69
Current: 13.47
During the past 13 years, the highest EV-to-EBITDA of Regeneron Pharmaceuticals was 37.69. The lowest was 6.36. And the median was 15.22.
LTS:0R2M's EV-to-EBITDA is ranked worse than 50.25% of 400
companies
in the Biotechnology industry
Industry Median: 13.485
vs LTS:0R2M: 13.47
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Regeneron Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Regeneron Pharmaceuticals's share price for today is $804.51.
Regeneron Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $40.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R2M vs RVMD, ALNY, ONC: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Regeneron Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's EV-to-EBITDA falls into.
Regeneron Pharmaceuticals's current Enterprise Value is $77,434 Mil.
Regeneron Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5,750 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals (LTS:0R2M) has a EV-to-EBITDA of 13.47 as of Aug. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Regeneron Pharmaceuticals. This is 11% below median its historical median of 15.22. Over the past decade, Regeneron Pharmaceuticals' EV-to-EBITDA has ranged from 6.36 to 37.69. According to the industry distribution chart, Regeneron Pharmaceuticals ranks #201 out of 400 companies in the Biotechnology industry, placing it in the top 50.2%.
Is Regeneron Pharmaceuticals' EV-to-EBITDA too high?
Regeneron Pharmaceuticals' current EV-to-EBITDA of 13.47 is 11% below median its 10-year median of 15.22. Over the past 10 years, this metric has ranged from a low of 6.36 to a high of 37.69. The Biotechnology industry median EV-to-EBITDA is 13.49. Regeneron Pharmaceuticals' value of 13.47 is 0.1% below this industry median. Based on the distribution chart, Regeneron Pharmaceuticals ranks #201 out of 400 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Regeneron Pharmaceuticals has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' EV-to-EBITDA compare to RVMD and ALNY?
According to the Biotechnology industry distribution chart, Regeneron Pharmaceuticals ranks #201 out of 400 companies for EV-to-EBITDA. This places Regeneron Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.49. Regeneron Pharmaceuticals' value of 13.47 is 0.1% below this benchmark. Historically, Regeneron Pharmaceuticals' own EV-to-EBITDA has ranged from 6.36 to 37.69 over the past decade. While the company's 10-year median is 15.22 vs. the industry median of 13.49, Regeneron Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.49, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regeneron Pharmaceuticals's current EV-to-EBITDA of 13.47 is 0.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Regeneron Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 13.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regeneron Pharmaceuticals's current EV-to-EBITDA is 13.47, which is 11% below median its own 10-year median of 15.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (LTS:0R2M) is currently considered Fairly Valued. The stock's GF Value™ is $865.71, compared to a current price of $804.51 — trading 7.1% below its estimated fair value. The current EV-to-EBITDA is 13.47, which is 11% below median its 10-year median of 15.22 and 0.1% below the Biotechnology industry median of 13.49. Regeneron Pharmaceuticals' overall GF Score™ is 89/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Regeneron Pharmaceuticals (LTS:0R2M), the current EV-to-EBITDA is 13.47 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (LTS:0R2M) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of $804.51 is trading 7.1% below its estimated GF Value™ of $865.71.
GuruFocus considers Regeneron Pharmaceuticals to be Fairly Valued.
Key valuation signals for LTS:0R2M:
EV-to-EBITDA: 13.47 (11% below median its 10-year median of 15.22)
GF Value™: $865.71 vs. price of $804.51 (7.1% below fair value)
Industry Position: 0.1% below the Biotechnology median (#201 of 400)
No single metric tells the full story. See the LTS:0R2M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
89GF Score
Get the complete analysis for LTS:0R2M
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R2M has been successfully added to your 
